|
1
|
Swerdlow SH, Campo E, Pileri SA, Harris
NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz
AD and Jaffe ES: The 2016 revision of the World Health Organization
classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Juárez-Salcedo LM and Castillo JJ:
Lymphoplasmacytic lymphoma and marginal zone lymphoma. Hematol
Oncol Clin North Am. 33:639–656. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zucca E, Arcaini L, Buske C, Johnson PW,
Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K,
Thieblemont C, et al: Marginal zone lymphomas: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 31:17–29. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rodríguez-Sevilla JJ and Salar A: Recent
advances in the genetic of MALT Lymphomas. Cancers (Basel).
14:1762021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rossi D, Bertoni F and Zucca E:
Marginal-zone lymphomas. N Engl J Med. 386:568–581. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coiffier B, Thieblemont C, Van Den Neste
E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M,
Sebban C, et al: Long-term outcome of patients in the LNH-98.5
trial, the first randomized study comparing rituximab-CHOP to
standard CHOP chemotherapy in DLBCL patients: a study by the Groupe
d'Etudes des Lymphomes de l'Adulte. Blood. 116:2040–2045. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luo C, Wu G, Huang X, Ma Y, Zhang Y, Song
Q, Xie M, Sun Y, Huang Y, Huang Z, et al: Efficacy and safety of
new anti-CD20 monoclonal antibodies versus rituximab for induction
therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review
and meta-analysis. Sci Rep. 11:32552021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kyriazopoulou L, Karpathiou G,
Hatzimichael E, Peoc'h M, Papoudou-Bai A and Kanavaros P: Autophagy
and cellular senescence in classical Hodgkin lymphoma. Pathol Res
Pract. 236:1539642022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ying H, Qu D, Liu C, Ying T, Lv J, Jin S
and Xu H: Chemoresistance is associated with Beclin-1 and PTEN
expression in epithelial ovarian cancers. Oncol Lett. 9:1759–1763.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang L, Liang X, Liu M, Wang W, Ma J, Guo
Q, Han L, Yang C and Nan K: Reduced expression of liver kinase B1
and Beclin1 is associated with the poor survival of patients with
non-small cell lung cancer. Oncol Rep. 32:1931–1938. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu T, Li Y, Gong L, Lu JG, Du XL, Zhang
WD, He XL and Wang JQ: Multi-step process of human breast
carcinogenesis: A role for BRCA1, BECN1, CCND1, PTEN and UVRAG. Mol
Med Rep. 5:305–312. 2012.PubMed/NCBI
|
|
12
|
Wang L, Zhang H, Sun M, Yin Z and Qian J:
High mobility group box 1-mediated autophagy promotes neuroblastoma
cell chemoresistance. Oncol Rep. 34:2969–2976. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cheah CY, Zucca E, Rossi D and Habermann
TM: Marginal zone lymphoma: Present status and future perspectives.
Haematologica. 107:35–43. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fiorentino V, Pizzimenti C, Pierconti F,
Lentini M, Ieni A, Caffo M, Angileri F, Tuccari G, Fadda G, Martini
M and Larocca LM: Unusual localization and clinical presentation of
primary central nervous system extranodal marginal zone B-cell
lymphoma: A case report. Oncol Lett. 26:4082023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zucca E, Rossi D and Bertoni F: Marginal
zone lymphomas. Hematol Oncol. 41 (Suppl 1):S88–S91. 2023.
View Article : Google Scholar
|
|
16
|
Ye J, Zhang J, Zhu Y, Wang L, Jiang X, Liu
B and He G: Targeting autophagy and beyond: Deconvoluting the
complexity of Beclin-1 from biological function to cancer therapy.
Acta Pharm Sin B. 13:4688–4714. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nicotra G, Mercalli F, Peracchio C,
Castino R, Follo C, Valente G and Isidoro C: Autophagy-active
beclin-1 correlates with favourable clinical outcome in non-Hodgkin
lymphomas. Mod Pathol. 23:937–950. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Avsec D, Djordjevič AT, Kandušer M,
Podgornik H, Škerget M and Mlinarič-Raščan I: Targeting autophagy
triggers apoptosis and complements the action of venetoclax in
chronic lymphocytic leukemia cells. Cancers (Basel). 13:45572021.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Valente G, Morani F, Nicotra G, Fusco N,
Peracchio C, Titone R, Alabiso O, Arisio R, Katsaros D, Benedetto C
and Isidoro C: Expression and clinical significance of the
autophagy proteins BECLIN 1 and LC3 in ovarian cancer. Biomed Res
Int. 2014:4626582014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang S, Huang F, Wang J, You R, Huang Q
and Chen Y: SQSTM1/p62 predicts prognosis and upregulates the
transcription of CCND1 to promote proliferation in mantle cell
lymphoma. Protoplasma. 262:635–647. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McCarthy A, Marzec J, Clear A, Petty RD,
Coutinho R, Matthews J, Wilson A, Iqbal S, Calaminici M, Gribben JG
and Jia L: Dysregulation of autophagy in human follicular lymphoma
is independent of overexpression of BCL-2. Oncotarget.
5:11653–11668. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li-Harms X, Milasta S, Lynch J, Wright C,
Joshi A, Iyengar R, Neale G, Wang X, Wang YD, Prolla TA, et al:
Mito-protective autophagy is impaired in erythroid cells of aged
mtDNA-mutator mice. Blood. 125:162–174. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Glick D, Barth S and Macleod KF:
Autophagy: Cellular and molecular mechanisms. J Pathol. 221:3–12.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu L, Chen Y and Tooze SA: Autophagy
pathway: Cellular and molecular mechanisms. Autophagy. 14:207–215.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alers S, Löffler AS, Wesselborg S and
Stork B: Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy:
Cross talk, shortcuts, and feedbacks. Mol Cell Biol. 32:2–11. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Levine B, Sinha S and Kroemer G: Bcl-2
family members: Dual regulators of apoptosis and autophagy.
Autophagy. 4:600–606. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Usman RM, Razzaq F, Akbar A, Farooqui AA,
Iftikhar A, Latif A, Hassan H, Zhao J, Carew JS, Nawrocki ST, et
al: Role and mechanism of autophagy-regulating factors in
tumorigenesis and drug resistance. Asia Pac J Clin Oncol.
17:193–208. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kang R, Zeh HJ, Lotze MT and Tang D: The
Beclin 1 network regulates autophagy and apoptosis. Cell Death
Differ. 18:571–580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vitto VAM, Bianchin S, Zolondick AA,
Pellielo G, Rimessi A, Chianese D, Yang H, Carbone M, Pinton P,
Giorgi C and Patergnani S: Molecular mechanisms of autophagy in
cancer development, progression, and therapy. Biomedicines.
10:15962022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rangel M, Kong J, Bhatt V, Khayati K and
Guo JY: Autophagy and tumorigenesis. FEBS J. 289:7177–7198. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Russell RC and Guan KL: The multifaceted
role of autophagy in cancer. EMBO J. 41:e1100312022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Levy JM and Thorburn A: Autophagy in
cancer: Moving from understanding mechanism to improving therapy
responses in patients. Cell Death Differ. 27:843–857. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chavez-Dominguez R, Perez-Medina M,
Lopez-Gonzalez JS, Galicia-Velasco M and Aguilar-Cazares D: The
double-edge sword of autophagy in cancer: From tumor suppression to
pro-tumor activity. Front Oncol. 10:5784182020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ahmadi-Dehlaghi F, Mohammadi P, Valipour
E, Pournaghi P, Kiani S and Mansouri K: Autophagy: A challengeable
paradox in cancer treatment. Cancer Med. 12:11542–11569. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pizzimenti C, Fiorentino V, Ruggeri C,
Franchina M, Ercoli A, Tuccari G and Ieni A: Autophagy involvement
in non-neoplastic and neoplastic endometrial pathology: The state
of the art with a focus on carcinoma. Int J Mol Sci. 25:121182024.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pandey A, Goswami A, Jithin B and Shukla
S: Autophagy: The convergence point of aging and cancer. Biochem
Biophys Rep. 42:1019862025.PubMed/NCBI
|
|
37
|
Debnath J, Gammoh N and Ryan KM: Autophagy
and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol.
24:560–575. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pizzimenti C, Fiorentino V, Franchina M,
Martini M, Giuffrè G, Lentini M, Silvestris N, Di Pietro M, Fadda
G, Tuccari G and Ieni A: Autophagic-related proteins in brain
gliomas: Role, mechanisms, and targeting agents. Cancers (Basel).
15:26222023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pizzimenti C, Curcio A, Fiorentino V,
Germanò A, Martini M, Ieni A and Tuccari G: Immunoexpression of
autophagy-related proteins in a single-center series of sporadic
adult conventional clival chordomas. Oncol Lett. 29:322025.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
García Ruiz O, Sánchez-Maldonado JM,
López-Nevot MÁ, García P, Macauda A, Hernández-Mohedo F, Veiga J,
Figuerola J, Videvall E and Martínez-de la Puente J: Autophagy in
Hematological Malignancies. Cancers (Basel). 14:50722022.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Buchner M and Müschen M: Targeting the
B-cell receptor signaling pathway in B lymphoid malignancies. Curr
Opin Hematol. 21:341–349. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Goldsmith J, Levine B and Debnath J:
Autophagy and cancer metabolism. Methods Enzymol. 542:25–57. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Poillet-Perez L, Sharp DW, Yang Y, Laddha
SV, Ibrahim M, Bommareddy PK, Hu ZS, Vieth J, Haas M, Bosenberg MW,
et al: Autophagy promotes growth of tumors with high mutational
burden by inhibiting a T-cell immune response. Nat Cancer.
1:923–934. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Choi J, Park G, Lee SSY, Dominici E,
Becker L, Macleod KF, Kron SJ and Hwang S: Context-dependent roles
for autophagy in myeloid cells in tumor progression. bioRxiv.
16:2024.07.12.603292. 2024.
|
|
45
|
Pattingre S and Levine B: Bcl-2 inhibition
of autophagy: A new route to cancer? Cancer Res. 66:2885–2888.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xu HD and Qin ZH: Beclin 1, Bcl-2 and
autophagy. Adv Exp Med Biol. 1206:109–126. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Minson A, Tam C, Dickinson M and Seymour
JF: Targeted agents in the treatment of indolent b-cell non-hodgkin
lymphomas. Cancers (Basel). 14:12762022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Warren CFA, Wong-Brown MW and Bowden NA:
BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis.
10:1772019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lamark T and Johansen T: Mechanisms of
selective autophagy. Annu Rev Cell Dev Biol. 37:143–169. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Schaaf MBE, Keulers TG, Vooijs MA and
Rouschop KMA: LC3/GABARAP family proteins: Autophagy-(un)related
functions. FASEB J. 30:3961–3978. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Galluzzi L and Green DR:
Autophagy-independent functions of the autophagy machinery. Cell.
177:1682–1699. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shaid S, Brandts CH, Serve H and Dikic I:
Ubiquitination and selective autophagy. Cell Death Differ.
20:21–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Amaravadi R, Kimmelman AC and White E:
Recent insights into the function of autophagy in cancer. Genes
Dev. 30:1913–1930. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Moscat J and Diaz-Meco MT: p62: A
versatile multitasker takes on cancer. Trends Biochem Sci.
37:230–236. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wei H, Wang C, Croce CM and Guan JL:
p62/SQSTM1 synergizes with autophagy for tumor growth in vivo.
Genes Dev. 28:1204–1216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Feng Y, Chen X, Cassady K, Zou Z, Yang S,
Wang Z and Zhang X: The role of mTOR inhibitors in hematologic
disease: From bench to bedside. Front Oncol. 10:6116902020.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ali ES, Mitra K, Akter S, Ramproshad S,
Mondal B, Khan IN, Islam MT, Sharifi-Rad J, Calina D and Cho WC:
Recent advances and limitations of mTOR inhibitors in the treatment
of cancer. Cancer Cell Int. 22:2842022. View Article : Google Scholar : PubMed/NCBI
|
